{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-CMDYMOTE/6c6eddc7-fd4b-4f80-96e2-a3cf0c83e5e5/HTML","dcterms:extent":"37 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-CMDYMOTE/041795d4-edef-4775-ba77-f29677d55ac1/PDF","dcterms:extent":"172 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-CMDYMOTE/7458f937-f7cd-4aae-91a1-dc8a5cad36b5/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-CMDYMOTE","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2004","dc:creator":["Drinovec, Jože","Modrijančič, Mojca","Mrhar, Aleš"],"dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:73"},{"@xml:lang":"sl","#text":"str. 53-57"}],"dc:identifier":["ISSN:1318-0347","COBISSID:1463665","URN:URN:NBN:SI:doc-CMDYMOTE"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"cardiovascular disease"},{"@xml:lang":"sl","#text":"epidemiologija"},{"@xml:lang":"sl","#text":"farmakoekonomika"},{"@xml:lang":"sl","#text":"kardiovaskularne bolezni"},{"@xml:lang":"sl","#text":"srčno popuščanje"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Some pharmacoeconomic aspects of congestive heart failure in Slovenia| Nekateri farmakoekonomski vidiki srčnega popuščanja v Sloveniji|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Congestive heart failure is a fatal disease. In view of its increasing frequency, primarily in the developed world and its aging population, it is becoming a major economic burden for the health care and whole society. Methods. A meta-analysis of effectiveness of convertase inhibitors and beta-blockers in the treatment of congestive heart failure was made. Based on epidemiological data collected in the region Bela krajina, we theoretically calculated the prevalence of congestive heart failure in Slovenia, visits at specialist doctors in a year, and determined hospitalization level. Also, we calculated the annual costs for each individual patient according to the classification made by the New York Heart Association (NYHA), total therapy costs for all patients with heart failure inSlovenia, the share of these costs in the total health care expenditures in Slovenia and in the gross national product. Results. Meta-analysis revealed effectiveness of the treatment of patients with heart failure with convertase inhibitors and beta-blockers with regard to reduced mortality as well as reduction of number of hospitalizations. Based on the epidemiological data from the region Bela krajina, the calculated prevalence of heart failure in the Slovene population was 1.11%, and the heart failure hospitalization level 1.37%. The annual costs of treatment of an individual patient with heart failure are increasing with progressive NYHA classes and amount to SIT 147,000.00 in NYHA class I, and SIT 1,672,000.00 in NYHA IV. Total costs of optimum treatment of the 40,000 patients with heart failure would in Slovenia amount to SIT 22,559,570,750.00, accounting for 7.07% of total health care expenditures and 0.56% of the gross national product. Conclusions. Prevalence of heart failure increases with age and is a considerable economic burden for the society"},{"@xml:lang":"sl","#text":"Izhodisea. Sreno popuseanje spada med usodne bolezni. Zaradi vse veeje pogostosti, predvsem v razvitejsem delu sveta s starajoeim se prebivalstvom, postaja pomembna obremenitev za zdravstvo in druzbo. Metode. Napravljena je bila metaanaliza ueinkovitosti konvertaznih zaviralcev in blokatorjev receptorjev beta pri srenem popuseanju. Na osnovi epidemioloskih podatkov na podroeju Bela krajina so avtorji teoretieno izraeunali prevalenco srenega popuseanja v celotni Sloveniji, stevilo letnih obiskov pri specialistu in poiskali stopnjo hospitalizacije. Na osnovi dobljenih epidemioloskih podatkov so izraeunali delez stroskov za posameznega bolnika s srenim popuseanjemletno glede na klasifikacijo po njujorskem kardioloskem zdruzenju, celokupne stroskeza vse bolnike s srenim popuseanjem v Sloveniji, delez v celotnih stroskih za zdravstveno varstvo ter del bruto nacionalnega dohodka. Rezultati.Metaanaliza je pokazala uspesnost pri zdravljenju bolnikov s srenim popuseanjem pri uporabi konvertaznih zaviralcev in blokatorjev receptorjev beta tako glede manjse smrtnosti kot hospitalizacije. Na osnovi epidemioloskihpodatkov podroeja Bela krajina je bila izraeunana prevalenca srenega popuseanja med slovenskim prebivalstvom 1,11%, stopnja hospitalizacijezaradi srenega popuseanja pa 1,37%. Letni stroski zdravljenja pri posameznem bolniku s srenim popuseanjem po razredih klasifikacije njujorskega kardioloskega zdruzenja naraseajo in veljajo v razredu I 147.000,00 SIT, v razredu IV pa 1.672.000,00 SIT. Celokupni stroski idealnega zdravljenja vseh 40.000 bolnikov s srenim popuseanjem v Sloveniji bi znasali 22.559.570.750,00 SIT, to bi pomenilo 7,07% sredstev za zdravstveno varstvo in0,56% bruto nacionalnega prihodka. Zakljueki. Prevalenca srenega popuseanja se poveeuje s starostjo in pomeni znatno ekonomsko obremenitev za druzbo"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-CMDYMOTE","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-CMDYMOTE"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-CMDYMOTE/041795d4-edef-4775-ba77-f29677d55ac1/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-CMDYMOTE/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-CMDYMOTE"}}}}